The European Medicines Agency will review GSK's request to approve its asthma drug Nucala as an additional treatment for ...

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils ...

EMA accepts for review GSK’s application to expand use of Nucala for COPD treatment: London, UK Wednesday, March 26, 2025, 11:00 Hrs [IST] GSK plc announced that the European Me ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results in ...

Researchers have uncovered changes in the cellular response throughout lung damage caused by SARS-CoV-2—the virus behind COVID-19. The team revealed distinct phases where waves of immune responses ...

In our 35th year we’re asking people to donate £35 – that’s just £1 for every year we’ve been providing ... to CMV colitis (gastrointestinal illness), pneumonitis (lung inflammation), encephalitis ...

Our SWIFT and ANCHOR trials support depemokimab’s potential to suppress interleukin-5 (IL-5), a known ... The phase III asthma programme consists of SWIFT-1 and SWIFT-2 in asthma with type 2 ...

Q4 2024 Results Conference Call March 20, 2025 8:00 AM ET. Company Participants. Andrew Funderburk - Senior Vice President, Investor Re ...

The table is a review of notable updates that occurred in February 2025 for investigational products in development.

Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Data From Cohorts 1-3 anticipated to be Presented in MayInitial Results From First Two ...

BLA accepted for review Dupilumab (Regeneron and Sanofi) Interleukin-4 receptor alpha ... contrast agent For detecting areas of active bowl inflammation in patients with Crohn disease.